AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31166415 — intervention group
Group type: EXPERIMENTAL
Intervention: Portland cement with added zirconium oxide (PCZ)
Number of subjects: 36
Study 31166415 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 28455182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous TXA (2 doses of 20 mg/kg)
Number of subjects: 560
Study 28455182 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical TXA (3.0 g)
Number of subjects: 560
Study 28455182 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral TXA (2 doses of 20 mg/kg)
Number of subjects: 560
Study 28455182 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 560
Study 27208386 — intervention group
Group type: EXPERIMENTAL
Intervention: DIMS0150 (30 mg)
Number of subjects: 131
Study 27208386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 24184120 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot examinations by primary health care nurses
Number of subjects: 265
Study 24184120 — intervention group
Group type: COMPARATOR
Intervention: Age group 51-65 years
Number of subjects: 265
Study 24184120 — intervention group
Group type: COMPARATOR
Intervention: Age group >66 years
Number of subjects: 265
Study 24184120 — intervention group
Group type: COMPARATOR
Intervention: Consultations by district nurses
Number of subjects: 265
Study 24184120 — intervention group
Group type: COMPARATOR
Intervention: Special programme consultations
Number of subjects: 265
Study 24184120 — intervention group
Group type: COMPARATOR
Intervention: Consultation length 15-30 min
Number of subjects: 265
Study 24184120 — intervention group
Group type: COMPARATOR
Intervention: Consultation length >30 min
Number of subjects: 265
Study 24184120 — intervention group
Group type: COMPARATOR
Intervention: Wound care consultations
Number of subjects: 265
Study 22585649 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein plus Plug (group B)
Number of subjects: 50
Study 22585649 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein Mesh (group A)
Number of subjects: 50
Study 19766942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral intervention
Number of subjects: 46
Study 19766942 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 46
Study 17532963 — intervention group
Group type: EXPERIMENTAL
Intervention: MC-1 250 mg
Number of subjects: 901
Study 15478487 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-etching agents (Prompt‐L Pop, Adper Prompt, Clearfil SE, Prime& Bond NT with NRC, Xeno111, One‐Up Bond, AdheSe)
Number of subjects: 120
Study 15478487 — intervention group
Group type: EXPERIMENTAL
Intervention: Total etch technique (36% H2PO4)
Number of subjects: 120
Study 11480451 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioner letter
Number of subjects: 1158
Study 11480451 — intervention group
Group type: EXPERIMENTAL
Intervention: Flag in women's notes prompting discussion by health professionals
Number of subjects: 1158
Study 11480451 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 1158
Study 11480451 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 1158
Study 9627258 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine (4 mg/kg of 2% lidocaine applied to subglottic, glottic, and supraglottic areas before intubation)
Number of subjects: 134
Study 9627258 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1 mg/kg of 2% lidocaine before extubation)
Number of subjects: 134
Study 9627258 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (used topically in the first control group)
Number of subjects: 134
Study 9627258 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (given to the second control group)
Number of subjects: 134
Study 8149770 — intervention group
Group type: EXPERIMENTAL
Intervention: Three levels of protein and phosphorus intake
Number of subjects: 0
Study 8149770 — intervention group
Group type: EXPERIMENTAL
Intervention: Two levels of blood pressure management
Number of subjects: 0
Study 3276150 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral miconazole
Number of subjects: 12
Study 3276150 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 12
Study 29733445 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 70 μg/d
Number of subjects: 81
Study 29733445 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg/d
Number of subjects: 81
Study 29733445 — intervention group
Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 81
Study 28804199 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity troponin I (hsTnI)
Number of subjects: 99
Study 28804199 — intervention group
Group type: EXPERIMENTAL
Intervention: High sensitivity troponin T (hsTnT)
Number of subjects: 99
Study 26304595 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II type I receptor blocker (ARB) medication
Number of subjects: 227
Study 26304595 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of eUUN or protein intake during ARB treatment
Number of subjects: 227
Study 23098134 — intervention group
Group type: COMPARATOR
Intervention: Ingesting all hypertension medications upon awakening
Number of subjects: 2659
Study 23098134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingesting ≥1 hypertension medications at bedtime
Number of subjects: 2659
Study 23098134 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingesting all hypertension medications at bedtime
Number of subjects: 2659
Study 21943044 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory women's group intervention with high population coverage
Number of subjects: 648
Study 21943044 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 648
Study 18315706 — intervention group
Group type: COMPARATOR
Intervention: Bolus intravenous furosemide
Number of subjects: 42
Study 18315706 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous furosemide infusion
Number of subjects: 42
Study 16849982 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - smoking cessation intervention
Number of subjects: 277
Study 16849982 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Group (UC) - control group
Number of subjects: 277
Study 12690278 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (25 mg/kg every 12 h)
Number of subjects: 167
Study 12690278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 15887897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling application (10 min with a cooling jacket)
Number of subjects: 14
Study 15887897 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery (control)
Number of subjects: 14
Study 10028446 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved ileal mucosa of patients with Crohn's disease
Number of subjects: 0
Study 10028446 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy and involved ileal mucosa of patients with Crohn's disease
Number of subjects: 0
Study 10028446 — intervention group
Group type: COMPARATOR
Intervention: Healthy mucosa of patients with Crohn's disease
Number of subjects: 0
Study 7537602 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex 50 mg daily for 24 weeks
Number of subjects: 27
Study 7537602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2404631 — intervention group
Group type: EXPERIMENTAL
Intervention: Colestipol plus niacin therapy
Number of subjects: 0
Study 2404631 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7000168 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg thrice daily)
Number of subjects: 37
Study 7000168 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31839533 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography/CT (PET/CT) scans replacing every other computed tomography (CT) scan
Number of subjects: 750
Study 31839533 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up scheme with CT scans (control group)
Number of subjects: 750
Study 30632692 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin 5 mg
Number of subjects: 0
Study 30632692 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 28697785 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic therapy program (12 weeks, aerobic and functional exercises in circuit training)
Number of subjects: 0
Study 28697785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 26416265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsi‐R (heavy rolling massage on the calf with higher tenderness)
Number of subjects: 150
Study 26416265 — intervention group
Group type: EXPERIMENTAL
Intervention: Contra‐R (heavy rolling massage on the contralateral calf)
Number of subjects: 150
Study 26416265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipsi‐M (manual massage on the calf with higher tenderness)
Number of subjects: 150
Study 26416265 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 150
Study 26416265 — intervention group
Group type: COMPARATOR
Intervention: Sham (light stroking of the skin with roller massager on the calf with higher tenderness)
Number of subjects: 150
Study 24283283 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 minutes brushing
Number of subjects: 0
Study 24283283 — intervention group
Group type: COMPARATOR
Intervention: 40 seconds brushing
Number of subjects: 0
Study 21221621 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Number of subjects: 455
Study 19647958 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg)
Number of subjects: 46
Study 19647958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 17898501 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-enriched oil (2.6g/14g of ALA)
Number of subjects: 0
Study 17898501 — intervention group
Group type: COMPARATOR
Intervention: Control oil (42g)
Number of subjects: 0
Study 15483801 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral joint line injection
Number of subjects: 131
Study 15483801 — intervention group
Group type: EXPERIMENTAL
Intervention: Superomedial injection
Number of subjects: 131
Study 15483801 — intervention group
Group type: EXPERIMENTAL
Intervention: Superolateral injection
Number of subjects: 131
Study 11679448 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction (WLoss group)
Number of subjects: 19
Study 11679448 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy restriction plus resistance training (RT + WLoss group)
Number of subjects: 19
Study 11679448 — intervention group
Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 19
Study 9044517 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracavernous injection of papaverine
Number of subjects: 28
Study 9044517 — intervention group
Group type: COMPARATOR
Intervention: Transdermal nitroglycerin
Number of subjects: 28
Study 8172713 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex 50 mg once daily
Number of subjects: 304
Study 8172713 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex 100 mg/day
Number of subjects: 304
Study 8172713 — intervention group
Group type: EXPERIMENTAL
Intervention: Casodex 150 mg/day
Number of subjects: 304
Study 8172713 — intervention group
Group type: COMPARATOR
Intervention: Castration (surgical or medical)
Number of subjects: 304
Study 30087040 — intervention group
Group type: COMPARATOR
Intervention: CDM Group-I (standard care)
Number of subjects: 269
Study 30087040 — intervention group
Group type: EXPERIMENTAL
Intervention: CDM Group-II (additional interventions including early postpartum follow-up and beta-blocker therapy)
Number of subjects: 269
Study 30087040 — intervention group
Group type: COMPARATOR
Intervention: CDM Group-I
Number of subjects: 269
Study 30087040 — intervention group
Group type: EXPERIMENTAL
Intervention: CDM Group-II
Number of subjects: 269
Study 30087040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 269
Study 27328484 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrification
Number of subjects: 2
Study 27328484 — intervention group
Group type: COMPARATOR
Intervention: Modified slow freeze protocol
Number of subjects: 2
Study 25684089 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based diet (PB)
Number of subjects: 30
Study 25684089 — intervention group
Group type: COMPARATOR
Intervention: American Heart Association diet (AHA)
Number of subjects: 30
Study 23106760 — intervention group
Group type: EXPERIMENTAL
Intervention: Group drug counseling with positive alliance with counselor
Number of subjects: 440
Study 23106760 — intervention group
Group type: EXPERIMENTAL
Intervention: Group drug counseling with advice from counselor and group members
Number of subjects: 440
Study 23106760 — intervention group
Group type: EXPERIMENTAL
Intervention: Group drug counseling with self-disclosure and participation
Number of subjects: 440
Study 23106760 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in process variables over time (linear slopes)
Number of subjects: 440
Study 20579938 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.2-0.4 mg daily)
Number of subjects: 251
Study 20579938 — intervention group
Group type: COMPARATOR
Intervention: Alarm
Number of subjects: 251
Study 18922243 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 5-10 mg/d
Number of subjects: 0
Study 18922243 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10-20 mg/d
Number of subjects: 0
Study 18922243 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/d
Number of subjects: 0
Study 17012890 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPw-HepB-Hib combination vaccine (Quinvaxem)
Number of subjects: 0
Study 17012890 — intervention group
Group type: COMPARATOR
Intervention: DTPw-Hib and hepatitis B vaccines (comparator group)
Number of subjects: 0
Study 14609821 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord serum therapy
Number of subjects: 59
Study 14609821 — intervention group
Group type: COMPARATOR
Intervention: Autologous serum therapy
Number of subjects: 59
Study 10921767 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg via Turbuhaler
Number of subjects: 36
Study 10921767 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 9 microg via Turbuhaler
Number of subjects: 36
Study 10921767 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 100 microg via pMDI
Number of subjects: 36
Study 10921767 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg via pMDI
Number of subjects: 36
Study 10921767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 9220839 — intervention group
Group type: EXPERIMENTAL
Intervention: Unna's boot and activated charcoal treatment
Number of subjects: 47
Study 1374061 — intervention group
Group type: EXPERIMENTAL
Intervention: Local + HBI (800 cGy)
Number of subjects: 499
Study 1374061 — intervention group
Group type: COMPARATOR
Intervention: Local only (300 cGy x 10)
Number of subjects: 499
Study 4018464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress (mental arithmetic and Sacks test)
Number of subjects: 130
Study 4018464 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise test
Number of subjects: 130
Study 4018464 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory ECG monitoring
Number of subjects: 130
Study 4018464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 130
Study 4018464 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental arithmetic
Number of subjects: 130
Study 30908136 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness coloring (mandala)
Number of subjects: 167
Study 30908136 — intervention group
Group type: EXPERIMENTAL
Intervention: Free drawing/coloring
Number of subjects: 167
Study 30908136 — intervention group
Group type: COMPARATOR
Intervention: Noncoloring control activity
Number of subjects: 167
Study 26558649 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized consent form with additional printed take-home material
Number of subjects: 100
Study 26558649 — intervention group
Group type: COMPARATOR
Intervention: Standardized consent form without additional printed take-home material
Number of subjects: 100
Study 26558649 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized consent form with written information
Number of subjects: 100
Study 26558649 — intervention group
Group type: COMPARATOR
Intervention: Standardized consent form without written information
Number of subjects: 100
Study 26667403 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (10 mg)
Number of subjects: 64
Study 26667403 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 64
Study 24218006 — intervention group
Group type: EXPERIMENTAL
Intervention: Basel cocktail (low doses of caffeine, efavirenz, losartan, omeprazole, metoprolol, midazolam)
Number of subjects: 16
Study 24218006 — intervention group
Group type: EXPERIMENTAL
Intervention: Basel cocktail
Number of subjects: 16
Study 24218006 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS or saliva samples
Number of subjects: 16
Study 22198456 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 84
Study 22198456 — intervention group
Group type: COMPARATOR
Intervention: Paroxetine
Number of subjects: 84
Study 20660832 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ICE
Number of subjects: 396
Study 20660832 — intervention group
Group type: COMPARATOR
Intervention: R-DHAP
Number of subjects: 396
Study 18310583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CCBT)
Number of subjects: 72
Study 18310583 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CCBT) followed by mirtazapine
Number of subjects: 72
Study 18310583 — intervention group
Group type: COMPARATOR
Intervention: Mirtazapine
Number of subjects: 72
Study 18310583 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 15650277 — intervention group
Group type: EXPERIMENTAL
Intervention: PregVit p.m. (1 tablet containing 1.1 mg of folic acid) administered in the morning
Number of subjects: 6
Study 15650277 — intervention group
Group type: EXPERIMENTAL
Intervention: PregVit p.m. (1 tablet containing 1.1 mg of folic acid) administered in the evening
Number of subjects: 6
Study 15650277 — intervention group
Group type: EXPERIMENTAL
Intervention: PregVit p.m. (morning administration)
Number of subjects: 6
Study 15650277 — intervention group
Group type: EXPERIMENTAL
Intervention: PregVit p.m. (evening administration)
Number of subjects: 6
Study 11828241 — intervention group
Group type: EXPERIMENTAL
Intervention: ULLS-CM (countermeasures)
Number of subjects: 32
Study 11828241 — intervention group
Group type: COMPARATOR
Intervention: ULLS-CON (control)
Number of subjects: 32
Study 11828241 — intervention group
Group type: EXPERIMENTAL
Intervention: AMB-CM (countermeasures)
Number of subjects: 32
Study 11828241 — intervention group
Group type: COMPARATOR
Intervention: AMB-CON (control)
Number of subjects: 32
Study 10405497 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.3 mg/kg per dose
Number of subjects: 11
Study 10405497 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) 0.6 mg/kg per dose
Number of subjects: 11
Study 10405497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 10405497 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 11
Study 7564509 — intervention group
Group type: EXPERIMENTAL
Intervention: L-asparaginase
Number of subjects: 154
Study 7564509 — intervention group
Group type: COMPARATOR
Intervention: Etoposide
Number of subjects: 154
Study 2374231 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural anesthesia with 0.33 ml.kg.‐1 0.25% bupivacaine before surgery (group A)
Number of subjects: 24
Study 2374231 — intervention group
Group type: COMPARATOR
Intervention: Caudal epidural anesthesia with 0.33 ml.kg.‐1 0.25% bupivacaine after surgery (group B)
Number of subjects: 24
Study 6773715 — intervention group
Group type: EXPERIMENTAL
Intervention: tocainide 600 mg three times daily for 8 weeks
Number of subjects: 41
Study 6773715 — intervention group
Group type: EXPERIMENTAL
Intervention: quinidine sulfate 300 mg four times daily for 8 weeks
Number of subjects: 41
Study 6773715 — intervention group
Group type: COMPARATOR
Intervention: placebo administered for 6 weeks
Number of subjects: 41
Study 30365198 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture wipe
Number of subjects: 152
Study 30365198 — intervention group
Group type: COMPARATOR
Intervention: Water rinse
Number of subjects: 152
Study 28641496 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine (3 mg/day)
Number of subjects: 0
Study 28641496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 27146258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50 μg (2000 IU) daily
Number of subjects: 42
Study 27146258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 27146258 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 50 μg per day
Number of subjects: 42
Study 24661355 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 75 μg (3000 IU) daily for 6 months
Number of subjects: 64
Study 24661355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 22539589 — intervention group
Group type: EXPERIMENTAL
Intervention: Trained (TR, n = 18, 4-month exercise program)
Number of subjects: 36
Study 22539589 — intervention group
Group type: COMPARATOR
Intervention: Nontrained (NT, n = 18)
Number of subjects: 36
Study 22539589 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposuction
Number of subjects: 36
Study 20350694 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated health monitoring (AHM) system in conjunction with SPAN-CHF disease management program
Number of subjects: 188
Study 20350694 — intervention group
Group type: COMPARATOR
Intervention: Specialized Primary and Networked Care in Heart Failure (SPAN-CHF) disease management program
Number of subjects: 188
Study 18936596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous parecoxib 40 mg followed by an additional dose of parecoxib 20 mg
Number of subjects: 0